BioLargo (BLGO) Q2 2024 earnings summary

Executive summary

• Achieved record Q2 2024 revenue of $5.0 million, up 247% year-over-year, with year-to-date revenue of $9.8 million and an annualized run rate of $19.5 million.

• Net loss for Q2 2024 was $780,000, with $669,000 attributed to non-cash equity compensation, and net loss narrowed from $1.6 million in Q2 2023.

• Positive cash flow from operations of $330,000 in the first six months, with $4.8 million in cash and $4 million in working capital.

• Net shareholder equity reached $5.9 million, with minimal long-term debt and total assets of $10.1 million.

• Growth driven by Pooph product expansion, new engineering contracts, and investments in medical and energy technology segments.

Financial highlights

• Q2 2024 revenue reached $5.0 million, a 247% increase year-over-year, with gross profit over $2.1 million and gross margin above 40%.

• Net loss for Q2 2024 was $780,000, largely due to non-cash charges such as stock options ($669,000).

• Cash flow from operations was positive, and cash and cash equivalents stood at $4.8 million.

• No new parent-level equity raises or private placements in Q2; warrant and option exercises contributed to capital.

• Net stockholder's equity was $5.9 million as of Q2 2024.

Outlook and guidance

• Management expects continued revenue growth, with Pooph targeting 20% quarter-over-quarter and 100% year-over-year expansion, aiming for presence in 80,000 stores.

• Clyra Medical's commercial launch is anticipated within 6-12 months, with significant revenue potential.

• Battery technology and PFAS water treatment solutions are positioned for future growth, with commercial accounts and partnerships in development.

• New product launches and category expansions are expected to drive further growth.

• Future revenues depend on partner performance and market adoption.